logo

Vertex Pharmaceuticals Inc. (VRTX)



Trade VRTX now with
  Date
  Headline
2/14/2018 8:36:12 AM Vertex Reports Treatment With NaV1.8 Inhibitor VX-150 Showed Significant Relief Of Acute Pain In Phase 2 Study
2/12/2018 4:53:04 PM Vertex: FDA OKs SYMDEKOTM For Underlying Cause Of Cystic Fibrosis In People Ages 12, Older With Mutations In CFTR Gene
2/1/2018 12:12:43 AM Vertex Selects VX-659 & VX-445 To Advance Into Phase 3 Development As Part Of Two Different Triple Combination Regimens
1/31/2018 4:06:16 PM Vertex Pharma Q4 Non-GAAP EPS $0.61 Vs $0.35 Last Year
1/10/2018 4:03:35 AM Vertex Receives EU Approval For ORKAMBI In Children With Cystic Fibrosis Ages 6-11 With Two Copies Of F508del Mutation
12/12/2017 8:32:39 AM Vertex And CRISPR Therapeutics To Co-develop And Co-commercialize CTX001
12/7/2017 8:04:54 AM Vertex Says Phase 3 Study Of KALYDECO (ivacaftor) Met Its Primary Endpoint
11/10/2017 7:31:56 AM Vertex Receives CHMP Positive Opinion For ORKAMBI For Children With Cystic Fibrosis Ages 6-11